GENELINK PARTNERS WITH DNAPRINT TO DEVELOP "NEXT GENERATION" GENETIC-PROFILE TESTS FOR PERSONALIZED COSMETICS
March 6, 2003

MARGATE, NJ - BUSINESS WIRE - March 6, 2003 - GeneLink BioSciences, Inc. (OTCBB:GNLK) announced today that it entered into a collaborative agreement with DNAPrint Genomics, Inc. (OTCBB:DNAP) whereby the companies will combine certain scientific and intellectual property resources to develop and market "next generation" genetic profile tests to the $100 Billion plus personal care and cosmetics industry. Further details were not disclosed.

GeneLink invented the first genetically-designed patentable DNA test for customized skin-care products, and DNAPrint brings its ultra-high throughput genotype capability and ADMIXMAP platform to the partnership. The companies anticipate screening millions of candidate markers to broaden proprietary product offerings.

Tests are designed to assess genetic risks for certain skin and nutritional deficiencies and provide a basis for recommending formulations that have been specifically designed to compensate for these deficiencies.

Rather than offering a "stand alone" genetic test, DNAPrint, GeneLink and other collaborative partner(s) (such as Arch Personal Care Products see news_articles) will link genetic assessments to a personalized solution for certain common dermatological and skin-aging problems. Current and future products are being offered to leading cosmetic industry marketers and manufacturers.

"GeneLink's Dermagenetics technologies are a breakthrough for the skin-care industry; they provide a viable means by which to personalize the selection of skin care products," says Tony Frudakis, DNAPrint's CEO. "We are very pleased to work together with GeneLink to co-develop new genetic assessments for a ready market place".

"DNAPrint is the leader in the measurement of population structures for disease genetics. GeneLink sees a significant opportunity to expand our industry leadership and patentable positions by combining scientific technologies with DNAPrint's ADMIXMAP capabilities," says John DePhillipo, GeneLink's CEO. He added, "By broadening our services and licensing opportunities, we increase immediate and future income opportunities for both companies."

About DNAPrint Genomics, Inc.: DNAPrint Genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. Using proprietary human genome research methods, the Company develops chemo-predictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and recreational genomics testing products. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.

About GeneLink: www.genelink.info. GeneLink BioSciences, Inc., a pioneer DNA banking and hereditary genetic information service has developed a proprietary method for genetic assessments (patents pending) and has begun to license these breakthrough nutragenetic and dermagenetic profiles to companies that market or manufacture products for the $100 billion plus skin care, nutritional supplement and health care industries.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.